Tumor-infiltrating lymphocytes (TILs) are frequently observed in several tumors, reflecting the dynamic process of '"cancer immunoediting"'. Prognostic and predictive values of TILs have been demonstrated in different cancers, proving their pivotal role in clinical outcome. In recent years, new therapies targeting immune checkpoint inhibitors, especially CTLA-4 and PD-1/PDL-1 pathways, have been introduced into clinical practice. In this context, TILs may even have a possible utility as a predictive biomarker for immunotherapy response. Areas covered: In this review, the authors summarize the most relevant knowledge related to TILs. This includes their prognostic and predictive significance in various types of tumour and the recent findings about their potential role in the cancer immunotherapy. Expert opinion: TILs evaluation could lead to a predictive biomarker for immunotherapy effectiveness in several cancer types. Furthermore, typing of TILs subpopulation could have clinical relevance in patient selection for treatment with immune checkpoint inhibitors. However further studies are still needed.

Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy? / Zito Marino, Federica; Ascierto, Paolo Antonio; Rossi, Giulio; Staibano, Stefania; Montella, Marco; Russo, Daniela; Alfano, Roberto; Morabito, Alessandro; Botti, Gerardo; Franco, Renato. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - 17:6(2017), pp. 735-746. [10.1080/14712598.2017.1309387]

Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?

Staibano, Stefania
Supervision
;
MONTELLA, MARCO
Methodology
;
Russo, Daniela
Methodology
;
Franco, Renato
2017

Abstract

Tumor-infiltrating lymphocytes (TILs) are frequently observed in several tumors, reflecting the dynamic process of '"cancer immunoediting"'. Prognostic and predictive values of TILs have been demonstrated in different cancers, proving their pivotal role in clinical outcome. In recent years, new therapies targeting immune checkpoint inhibitors, especially CTLA-4 and PD-1/PDL-1 pathways, have been introduced into clinical practice. In this context, TILs may even have a possible utility as a predictive biomarker for immunotherapy response. Areas covered: In this review, the authors summarize the most relevant knowledge related to TILs. This includes their prognostic and predictive significance in various types of tumour and the recent findings about their potential role in the cancer immunotherapy. Expert opinion: TILs evaluation could lead to a predictive biomarker for immunotherapy effectiveness in several cancer types. Furthermore, typing of TILs subpopulation could have clinical relevance in patient selection for treatment with immune checkpoint inhibitors. However further studies are still needed.
2017
Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy? / Zito Marino, Federica; Ascierto, Paolo Antonio; Rossi, Giulio; Staibano, Stefania; Montella, Marco; Russo, Daniela; Alfano, Roberto; Morabito, Alessandro; Botti, Gerardo; Franco, Renato. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - 17:6(2017), pp. 735-746. [10.1080/14712598.2017.1309387]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/697496
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 49
social impact